EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027

기사 요약

RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecting topline data in H2 2027.